Log in to search using one of your social media accounts:

 

NICE recommends Merck ’s erbitux to treat R/M SCCHN in oral cavity
The UK National Institute for Health and Care Excellence (NICE) has recommended the routine use of Merck ’s erbitux (cetuximab), in combination with platinum-based chemotherapy, to treat recurrent and / or metastatic (R/M) squamous cell carcinoma of t… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 9, 2017 Category: Pharmaceuticals Source Type: news

Results of NRG-RTOG 0436 highlight need for biomarkers in treatment of esophageal cancer
(NRG Oncology) NRG-RTOG 0436 has determined that adding an epidermal growth factor receptor (EGFR) inhibitor to a chemo-radiation regimen does not improve overall survival for patients with locally advanced esophageal cancer treated in a non-operative manner. These results are reported in 'Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients with Esophageal Cancer -- The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial,' which was recently published in the Journal of the American Medical Association Oncology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 25, 2017 Category: International Medicine & Public Health Source Type: news

Erbitux (Cetuximab) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 21, 2017 Category: Drugs & Pharmacology Source Type: news

Adding Cetuximab in Esophageal Cancer Fails to Improve Survival
Use of the EGFR inhibitor cetuximab with chemoradiation did not improve survival in patients with esophageal carcinoma compared with chemoradiation alone, according to the results of the phase III RTOG 0436 trial. (Source: CancerNetwork)
Source: CancerNetwork - July 13, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Esophageal Cancer Gastrointestinal Cancer News Source Type: news

SMAD4 loss is associated with cetuximab resistance and induction of MAPK/JNK activation in HNC
(InSilico Medicine, Inc.) The researchers identified that SMAD4 loss results in cetuximab resistance in vitro and poor survival in HPV-negative HNSCC patients and in vivo models. Using OncoFinder (an innovative bioinformatic tool currently rebranded as iPANDA), they revealed a signature of pro-survival and anti-apoptotic pathways specifically dysregulated in SMAD4-low HNSCCs and indicate JNK and MAPK activation as potential mediators of cetuximab resistance. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 7, 2017 Category: International Medicine & Public Health Source Type: news

Oh, Lovely: The Tick That Gives People Meat Allergies Is Spreading
By Megan Molteni for WIRED. First comes the unscratchable itching, and the angry blossoming of hives. Then stomach cramping, and — for the unluckiest few — difficulty breathing, passing out, and even death. In the last decade and a half, thousands of previously protein-loving Americans have developed a dangerous allergy to meat. And they all have one thing in common: the lone star tick. Red meat, you might be surprised to know, isn’t totally sugar-free. It contains a few protein-linked saccharides, including one called galactose-alpha-1,3-galactose, or alpha-gal, for short. More and more people are lear...
Source: Healthy Living - The Huffington Post - June 20, 2017 Category: Consumer Health News Source Type: news

Adding vemurafenib doubles progression-free survival in BRAF metastatic colorectal cancer
(University of Colorado Anschutz Medical Campus) Clinical trial results presented in an oral abstract session 3:00pm Monday, June 5 at the American Society for Clinical Oncology (ASCO) Annual Meeting 2017 shows promising results for the addition of vemurafenib (anti-BRAF) to treatment with cetuximab and irinotecan (anti-EGFR) in patients with metastatic colorectal cancer that have a BRAF V600E mutation. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 5, 2017 Category: Cancer & Oncology Source Type: news

NICE recommends Merck ’s Erbitux to treat patients with metastatic colorectal cancer
The UK National Institute for Health and Care Excellence (NICE) has issued a positive final appraisal determination (FAD) for Merck ’s Erbitux (cetuximab) to treat patients with RAS wild-type metastatic colorectal cancer (mCRC). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 3, 2017 Category: Pharmaceuticals Source Type: news

Addition of Vemurafenib to Irinotecan/Cetuximab Delayed Progression in BRAF-Mutated mCRC
The addition of the BRAF inhibitor vemurafenib to irinotecan and cetuximab prolonged progression-free survival and resulted in a higher disease control rate than treatment with irinotecan and cetuximab alone in patients with BRAF-mutant metastatic colorectal cancer. (Source: CancerNetwork)
Source: CancerNetwork - January 24, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO 2017 Gastrointestinal Cancers Symposium Colorectal Cancer News Source Type: news

Vemurafenib Delayed Progression in Metastatic, BRAF-Mutant CRC
This video covers results of the SWOG 1406 study, which tested the BRAF inhibitor vemurafenib in combination with irinotecan and cetuximab for patients with metastatic, BRAF-mutant colorectal cancer. (Source: CancerNetwork)
Source: CancerNetwork - January 23, 2017 Category: Cancer & Oncology Authors: Scott Kopetz, MD Tags: Conferences/ASCO 2017 Gastrointestinal Cancers Symposium Videos Gastrointestinal Cancers Source Type: news

Cetuximab Reduces Locoregional Failure in Anal Canal Carcinoma, Adds Toxicity
Adding cetuximab to chemoradiation yielded better locoregional failure rates than historical data in a small trial of patients with squamous cell carcinoma of the anal canal, but the treatment resulted in substantial toxicity. (Source: CancerNetwork)
Source: CancerNetwork - January 11, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gastrointestinal Cancer News Source Type: news

[Research Article] The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor
The kinase AXL promotes cetuximab resistance by promoting the nuclear accumulation of EGFR. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - January 3, 2017 Category: Science Authors: Toni M. Brand, Mari Iida, Kelsey L. Corrigan, Cara M. Braverman, John P. Coan, Bailey G. Flanigan, Andrew P. Stein, Ravi Salgia, Jana Rolff, Randall J. Kimple, Deric L. Wheeler Source Type: news

Roadmap to more personalized cancer treatment
People with advanced head and neck squamous cell carcinoma and the KRAS-variant inherited genetic mutation have significantly improved survival when given a short course of the drug cetuximab in combination with standard chemotherapy and radiation, research has found. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 22, 2016 Category: Science Source Type: news

Study provides roadmap to more personalized cancer treatment
Milo Mitchell/UCLA Jonsson Comprehensive Cancer CenterUCLA ’s Dr. Joanne Weidhaas explains her latest research, which could lead to more personalized treatments for head and neck cancer. FINDINGSResearchers have found that people with advanced head and neck squamous cell carcinoma and the KRAS-variant inherited genetic mutation have significantly improved survival when given a short course of the drug cetuximab in combination with standard chemotherapy and radiation.The study was led by UCLA Jonsson Comprehensive Cancer Center member Dr. Joanne Weidhaas in collaboration with colleagues at the NRG Oncology RTOG. ...
Source: UCLA Newsroom: Health Sciences - December 22, 2016 Category: Universities & Medical Training Source Type: news

Researchers find key to drug resistant bowel cancer
Blcoking a molecule could bypass bowel cancer ’s defense against the drug cetuximab, according to new research. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 9, 2016 Category: Science Source Type: news

Researcher finds key to drug resistant bowel cancer
(Cancer Research UK) Blocking a molecule could bypass bowel cancer's defence against the drug cetuximab, according to new research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 8, 2016 Category: Cancer & Oncology Source Type: news

Cetuximab Continuation After First Progression in CRC Cetuximab Continuation After First Progression in CRC
Which molecular markers indicate that continuation of cetuximab in second-line therapy for colorectal cancer may be effective?Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 12, 2016 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Cetuximab Continuation After CRC Progression May Up PFS Cetuximab Continuation After CRC Progression May Up PFS
Dr David Kerr reports on a phase 2 study suggesting that continuation of cetuximab after progression may improve progression-free survival in patients with metastatic colorectal cancer. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 22, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Cetuximab Plus RT Not Ready for Prime Time in Laryngeal CancerCetuximab Plus RT Not Ready for Prime Time in Laryngeal Cancer
Outcomes favor cetuximab plus radiotherapy vs radiotherapy alone in laryngeal cancer, even though results are not statistically significant. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 7, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Combination chemo-radiation therapy may help preserve larynx for patients with laryngeal cancer
Researchers assessed the rates of laryngeal (having to do with the larynx [voice box]) preservation and laryngectomy-free survival in patients receiving the monoclonal antibody cetuximab and radiation therapy (CRT) or radiation therapy alone. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 7, 2016 Category: Science Source Type: news

Combination chemo-radiation therapy may help preserve larynx for patients with laryngeal cancer
(The JAMA Network Journals) In a study published online by JAMA Otolaryngology-Head & Neck Surgery, James A. Bonner, M.D., of the University of Alabama at Birmingham, and colleagues assessed the rates of laryngeal (having to do with the larynx [voice box]) preservation and laryngectomy-free survival in patients receiving the monoclonal antibody cetuximab and radiation therapy (CRT) or radiation therapy alone. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 7, 2016 Category: Cancer & Oncology Source Type: news

Merck reports positive pivotal Phase III TAILOR study results of Erbitux and FOLFOX combination for mCRC
Merck has reported a positive outcome of pivotal Phase III TAILOR study of the combination of Erbitux (cetuximab) and FOLFOX to treat RAS wild-type, metastatic colorectal cancer (mCRC). (Source: Drug Development Technology)
Source: Drug Development Technology - July 3, 2016 Category: Pharmaceuticals Source Type: news

Cetuximab, panitumumab not cost effective for RAS WT CRC
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - May 31, 2016 Category: Drugs & Pharmacology Source Type: news

Blood marker determines who will respond to colorectal cancer drug
Cancer researchers have identified a marker that shows up in a blood test that determines which patients with colorectal cancer that has spread would benefit from receiving the drug cetuximab. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 13, 2016 Category: Science Source Type: news

Findings expand potential of cancer drug
(Queen's University) New research from the Canadian Cancer Trials Group has discovered that a new subset of patients with metastatic colorectal cancer could benefit from taking the drug cetuximab. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 13, 2016 Category: Cancer & Oncology Source Type: news

Researchers find blood marker that determines who will respond to colorectal cancer drug
(University Health Network) Cancer researchers have identified a marker that shows up in a blood test that determines which patients with colorectal cancer that has spread would benefit from receiving the drug cetuximab. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 13, 2016 Category: Global & Universal Source Type: news

Merck reports positive results form Chinese Phase III TAILOR trial of Erbitux-Folfox combination
Merck has reported that the Chinese Phase III TAILOR study has demonstrated positive results of Erbitux (cetuximab) plus Folfox chemotherapy, compared with Folfox alone in patients with RAS wild-type metastatic colorectal cancer (mCRC). (Source: Drug Development Technology)
Source: Drug Development Technology - April 25, 2016 Category: Pharmaceuticals Source Type: news

New Liquid Biopsy RAS Testing For Metastatic Colorectal Cancer Patients Now Available For Clinical Practices
Sysmex Inostics, a subsidiary of Sysmex Corporation, today announced that its OncoBEAM® RAS CRC test has been granted CE Mark approval. The test, developed by Sysmex Inostics GmbH in collaboration with Merck, can now be accessed by patients with metastatic colorectal cancer (mCRC) across Europe. The OncoBEAM® RAS CRC assay has been shown to have similar performance to conventional tissue-based testing[1]-[3] and can be used to determine which patients would benefit from anti-EGFR therapies, such as Erbitux, as demonstrated by recent data. (Source: Medical Design Online News)
Source: Medical Design Online News - April 8, 2016 Category: Medical Equipment Source Type: news

Cuba Has Made At Least 3 Major Medical Innovations That We Need
By most measures, the United States' business-friendly environment has proven to be fertile for medical innovation. Compared to other countries, America has filed the most patents in the life sciences, is conducting most of the world's clinical trials and has published the most biomedical research. That's what makes the medical prominence of Cuba all the more surprising to those who view a free market as an essential driver of scientific discovery. Cuba is very poor, and yet the country has some of the healthiest, most long-lived residents in the world -- as well as a medical invention or two that could run circl...
Source: Science - The Huffington Post - March 15, 2016 Category: Science Source Type: news

Research points to why some colorectal cancers recur after treatment
(University of Texas M. D. Anderson Cancer Center) Cetuximab, marketed as Erbitux, is one of the key therapies for metastatic colorectal cancer. Yet the cancer still returns in some patients, shortening overall survival. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 16, 2015 Category: Cancer & Oncology Source Type: news

Research points to why some colorectal cancers recur after treatment
Cetuximab, marketed as Erbitux®, is one of the key therapies for metastatic colorectal cancer. Yet the cancer still returns in some patients, shortening overall survival. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - November 16, 2015 Category: Cancer & Oncology Source Type: news

Cetuximab Benefits Select Patients With Advanced Lung CancerCetuximab Benefits Select Patients With Advanced Lung Cancer
Adding cetuximab to chemotherapy failed to improve outcomes in the overall population of patients with non-small-cell lung cancer, but did confer a benefit in certain subgroups. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 16, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Cetuximab Finds Niche in Non-Small Cell Lung Cancer (CME/CE)
(MedPage Today) -- Significant survival improvement in squamous, EGFR+ subgroup (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - September 13, 2015 Category: Geriatrics Source Type: news

Medtech approvals: FDA releases May 2015 PMAs
The FDA today released its list of the pre-market approvals it granted for medical devices in May 2015: Summary of PMA Originals & Supplements Approved Originals: 5 Supplements: 51 Summary of PMA Originals Under Review Total Under Review: 55 Total Active: 26 Total On Hold: 29 Summary of PMA Supplements Under Review Total Under Review: 547 Total Active: 379 Total On Hold: 168 Summary of All PMA Submissions Originals: 1 Supplements: 62 Summary of PMA Supplement PMA Approval/Denial Decision Times Number of Approvals: 51 Number of Denials: 0 Average Days Fr Receipt to Decision (Total Time): 109.5 FDA Time: 86...
Source: Mass Device - August 6, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Food & Drug Administration (FDA) Regulatory/Compliance Source Type: news

Are Cetuximab Study Critics Acting Like Don Quixote?Are Cetuximab Study Critics Acting Like Don Quixote?
A group of investigators said the drug should not be used in a specific type of metastatic colorectal cancer. A group of critics disagrees. The argument continues. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 10, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Colorectal cancer: Second-line cetuximab active beyond progression in quadruple wild-type patients with mcrc
Patients with metastatic colorectal cancer (mCRC) that are mutation-free in the KRAS, NRAS, BRAF and PIK3CA genes showed significant benefit from continuing anti-epidermal growth factor receptor (EGFR) therapy beyond progression following first-line chemotherapy and an anti-EGFR monoclonal antibody, according to new study results. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 4, 2015 Category: Science Source Type: news

Second-line cetuximab active beyond progression in quadruple wild-type patients with mCRC
(European Society for Medical Oncology) Patients with metastatic colorectal cancer (mCRC) that are mutation-free in the KRAS, NRAS, BRAF and PIK3CA genes showed significant benefit from continuing anti-epidermal growth factor receptor (EGFR) therapy beyond progression following first-line chemotherapy and an anti-EGFR monoclonal antibody, according to study results presented at the ESMO 17th World Congress on Gastrointestinal Cancer in Barcelona, Spain. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 4, 2015 Category: Cancer & Oncology Source Type: news

New Immune Therapies Show Major Promise In Shrinking Cancer Tumors
CHICAGO (AP) — For the first time, a major study shows that a drug targeting the body's disease-fighting immune system may improve survival for the most common form of lung cancer. These newer kinds of drugs have transformed treatment of melanoma, the deadliest kind of skin cancer. Studies presented at a conference Friday suggest these "immune therapies" can play a broader role in more common cancers, including lung, liver, colon and head and neck. Doctors also may have found a way to help predict which patients would respond best to one of these newer treatments, according to research presented at the Ch...
Source: Science - The Huffington Post - June 1, 2015 Category: Science Source Type: news

A better biomarker to predict cetuximab response in CRC patients
(InSilico Medicine, Inc.) Scientists at Insilico Medicine, Inc. and Champions Oncology, Inc. have successfully demonstrate a method to predict response to cetuximab in patients with colorectal cancer using OncoFinder pathway activation strength. The study identified a novel prognostic marker in colorectal cancer treated with cetuximab. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 7, 2015 Category: Global & Universal Source Type: news

Erbitux Colorectal Cancer Treatment Market Analysis and Forecast to...
This report focuses on the current treatment landscape, unmet needs, current pipeline and...(PRWeb December 23, 2014)Read the full story at http://www.prweb.com/releases/erbitux-colorectal-cancer/market-analysis-to-2023/prweb12413234.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 25, 2014 Category: Pharmaceuticals Source Type: news

JCO Withdraws Editorial on Cetuximab for Metastatic CRCJCO Withdraws Editorial on Cetuximab for Metastatic CRC
The editorial critiqued the negative findings of a major clinical trial and discouraged clinicians from following the trial investigators' conclusion. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 25, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Three drugs may be better than one for certain patients with advanced colorectal cancer
(ECCO-the European CanCer Organisation) Patients with a form of advanced colorectal cancer that is driven by a mutated version of the BRAF gene have limited treatment options available. However, results, reported at the 26th EORTC-NCI-AACR Symposium, from a multi-center clinical trial suggest that the cancer may respond to a combination of three targeted drugs: encorafenib, cetuximab and alpelisib. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 20, 2014 Category: Global & Universal Source Type: news

Tomotherapy and Cetuximab for Unresectable SCC of the SkinTomotherapy and Cetuximab for Unresectable SCC of the Skin
This case report describes a novel approach to unresectable squamous cell carcinoma, utilizing radiation therapy in conjunction with an EGFR-inhibitor. BMC Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 17, 2014 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

TP53 Mutational Status and Cetuximab Benefit in Rectal CancerTP53 Mutational Status and Cetuximab Benefit in Rectal Cancer
Get the latest on locally advanced rectal cancer treatment from this updated analysis of the EXPERT-C trial. Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 23, 2014 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

FOLFIRI Plus Cetuximab vs Bevacizumab for Some Colorectal CancersFOLFIRI Plus Cetuximab vs Bevacizumab for Some Colorectal Cancers
In patients with KRAS exon 2 wild-type metastatic colorectal cancer (MCC) who received first-line FOLFIRI (fluorouracil, folinic acid and irinotecan), adding cetuximab rather than bevacizumab yielded longer overall survival. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 28, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

ESMO: Erbitux No Help in Esophageal Ca (CME/CE)
(MedPage Today) -- Survival in esophageal cancer did not improve with the addition of cetuximab (Erbitux) to conventional chemoradiation, results of a randomized trial showed. The study was among several notable reports from the European Society for Medical Oncology World Congress on Gastrointestinal Cancer. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - July 2, 2014 Category: Primary Care Source Type: news

Cetuximab or bevacizumab with combi chemo equivalent in KRAS wild-type MCRC
For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 29, 2014 Category: Science Source Type: news

Cetuximab or bevacizumab with combi chemo equivalent in KRAS wild-type MCRC
(European Society for Medical Oncology) For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 28, 2014 Category: Biology Source Type: news

Alchemia begins patient enrolment for Phase II trial of HA-Irinotecan and Erbitux
Australia-based Alchemia has started patient enrolment of the new clinical trial of HA-Irinotecan and Erbitux (cetuximab) called the CHIME trial. (Source: Drug Development Technology)
Source: Drug Development Technology - June 23, 2014 Category: Pharmaceuticals Source Type: news

Colon Cancer Alliance - high out-of-pocket costs
The Colon Cancer Alliance is committed to providing support and empowerment to those who are affected by colon cancer. This is why we’re actively addressing the patient impact of high out-of-pocket costs for medicine.  Due to increased costs, patients are making decisions about treatment based on financial implication as opposed to selecting the best treatment path to address their current condition.  The Affordable Care Act and Health Insurance Exchanges were intended to address the need for affordable care. The new Avelere study supports the patient stories we often hear. High copays and deductibles can c...
Source: PHRMA - June 13, 2014 Category: Pharmaceuticals Authors: Sabrina Source Type: news